Nuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio

Reuters01-30

Nuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio

Nuwellis, Inc. has entered into a definitive agreement to acquire all outstanding shares of Rendiatech Ltd., an Israeli-based medical technology company specializing in automated kidney function monitoring. The acquisition is intended to enhance Nuwellis’ cardiorenal portfolio by expanding its capabilities from therapeutic fluid removal into real-time renal monitoring. Following the completion of the transaction, Nuwellis plans to integrate Rendiatech’s Clarity™ system, which offers automated, continuous renal monitoring through precise urine-output measurement, into its existing commercial infrastructure. This move is expected to lay the groundwork for future advancements in urine-based analytics and broader kidney function assessment. The transaction has been approved by the boards of directors of both companies and is expected to close following customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607105141?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 05:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607105141","market":"fut","top_or_hot":-1,"title":"Nuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUWE\">Nuwellis, Inc.</a> has entered into a definitive agreement to acquire all outstanding shares of Rendiatech Ltd., an Israeli-based medical technology company specializing in automated kidney function monitoring. The acquisition is intended to enhance Nuwellis’ cardiorenal portfolio by expanding its capabilities from therapeutic fluid removal into real-time renal monitoring. Following the completion of the transaction, Nuwellis plans to integrate Rendiatech’s Clarity™ system, which offers automated, continuous renal monitoring through precise urine-output measurement, into its existing commercial infrastructure. This move is expected to lay the groundwork for future advancements in urine-based analytics and broader kidney function assessment. The transaction has been approved by the boards of directors of both companies and is expected to close following customary conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 05:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUWE\">Nuwellis, Inc.</a> has entered into a definitive agreement to acquire all outstanding shares of Rendiatech Ltd., an Israeli-based medical technology company specializing in automated kidney function monitoring. The acquisition is intended to enhance Nuwellis’ cardiorenal portfolio by expanding its capabilities from therapeutic fluid removal into real-time renal monitoring. Following the completion of the transaction, Nuwellis plans to integrate Rendiatech’s Clarity™ system, which offers automated, continuous renal monitoring through precise urine-output measurement, into its existing commercial infrastructure. This move is expected to lay the groundwork for future advancements in urine-based analytics and broader kidney function assessment. The transaction has been approved by the boards of directors of both companies and is expected to close following customary conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL1NCQqZ:1","article_id":"2607105141","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607105141","pubTimestamp":1769722772,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuwellis, Inc. has entered into a definitive agreement to acquire all outstanding shares of Rendiatech Ltd., an Israeli-based medical technology company specializing in automated kidney function monitoring. The acquisition is intended to enhance Nuwellis’ cardiorenal portfolio by expanding its capabilities from therapeutic fluid removal into real-time renal monitoring. Following the completion of the transaction, Nuwellis plans to integrate Rendiatech’s Clarity system, which offers automated, continuous renal monitoring through precise urine-output measurement, into its existing commercial infrastructure. This move is expected to lay the groundwork for future advancements in urine-based analytics and broader kidney function assessment. The transaction has been approved by the boards of directors of both companies and is expected to close following customary conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","NUWE":"Nuwellis, Inc."},"translate_title":"Nuwellis将收购Rendiatech以扩大心肾产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUWE":0.9},"content_text":"Nuwellis to Acquire Rendiatech in Move to Expand Cardiorenal Portfolio\n    \n\nNuwellis, Inc. has entered into a definitive agreement to acquire all outstanding shares of Rendiatech Ltd., an Israeli-based medical technology company specializing in automated kidney function monitoring. The acquisition is intended to enhance Nuwellis’ cardiorenal portfolio by expanding its capabilities from therapeutic fluid removal into real-time renal monitoring. Following the completion of the transaction, Nuwellis plans to integrate Rendiatech’s Clarity™ system, which offers automated, continuous renal monitoring through precise urine-output measurement, into its existing commercial infrastructure. This move is expected to lay the groundwork for future advancements in urine-based analytics and broader kidney function assessment. The transaction has been approved by the boards of directors of both companies and is expected to close following customary conditions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607105141","isCrawlerRequest":true}